Kyobo Life restarts IPO plans as it seeks to soothe investors Korean life insurer unlikely to price the offering high enough to satisfy financial investors
Translated by Ryu Ho-joung 공개 2021-11-19 09:03:43
이 기사는 2021년 11월 19일 08:02 thebell 에 표출된 기사입니다.
Kyobo Life Insurance has decided to restart preparations for an initial public offering as the South Korean insurer seeks to deescalate the dispute with its financial investors.The decision was made by the company’s board of directors on Tuesday, according to industry sources. Kyobo Life plans to file an IPO application next month, with a target of listing in the first half of 2022.
Kyobo Life said the recent rise in market interest rates has helped create better conditions for insurers to raise funds. However, most of life insurance companies listed in Seoul have seen their stock prices decline in recent years, largely due to a negative industry outlook and tightened regulations.
Shares in Samsung Life Insurance, the country’s number one life insurer, recently traded at around 65,000 won ($55.08), compared to its 110,000 won IPO price in May 2010. The stock prices of Hanwha Life Insurance, Tongyang Life Insurance and Mirae Asset Life Insurance have all been halved from their IPO prices.
The price-to-book (P/B) ratio is commonly used to value life insurance companies. The average P/B ratio for South Korean life insurers is around 0.3 as of November 2021, with 0.31 for Samsung Life, 0.22 for Hanwha Life, 0.36 for Tongyang Life and 0.34 for Mirae Asset Life.
Kyobo Life’s valuation is estimated at between 3 trillion won and 4 trillion won based on the average P/B ratio of 0.3 and the company’s shareholders equity of 12.27 trillion won at the end of September 2021.
This valuation significantly falls short of expectations of a consortium led by Affinity Equity Partners, which together own 24% of the insurer.
Kyobo Life’s valuation was estimated at up to 7 trillion won when the company prepared for an IPO in 2015. The investor group also exercised put options included in the shareholder agreement in 2018 to sell their stakes to Kyobo Life’s chief executive Shin Chang-jae at 409,000 won per share, which would value the company at more than 8 trillion won.
This is a reason why many observers expect Kyobo Life is unlikely to expedite the IPO and believe that the insurer decided to resume the IPO process in order to show its willingness to help the investors exit their investment in the company as a legal battle between the two sides intensifies.
It is said that Lee Chul-joo, an outside director representing the Affinity-led consortium, also attended the board meeting on Tuesday.
A Seoul court is expected to release a ruling on the case against officials from the investor group and accountants at Deloitte Anjin, who were indicted earlier this year for allegedly mispricing shares subject to the put options, before the end of this year. (Reporting by Eun-sol Lee)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- '재무개선' AJ네트웍스, 조달비용 '확' 낮췄다
- '9년만에 엑시트' 한앤코, 한온시스템 거래구조 살펴보니
- 한국타이어앤테크놀로지, 한온시스템 인수한다
- [수술대 오른 커넥트웨이브]2대주주 지분매입 나선 MBK, 주식교환 카드 꺼냈다
- [이사회 모니터]이재용 에이비프로바이오 대표, 바이오·반도체 신사업 '드라이브'
- 와이투솔루션, 주인 바뀌어도 '신약' 중심엔 美 합작사 '룩사'
- 아이티센, 부산디지털자산거래소 본격 출범
- 아이에스시, AI·데이터센터 수주 증가에 '날개'
- [이사회 모니터]서정학 IBK증권 대표, ESG위원회도 참여 '영향력 확대'
- SW클라우드 '10주년' 폴라리스오피스, “초격차 밸류업”